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CytokineCytokine signalling pathways that depend on gp130 are dysregulated in several epithelial cancers including
gastric cancer. It has been established that blockade of SHP2 activation of MAPK signalling results in
hyperactivation of STAT3 resulting in increased cell proliferation, angiogenesis, inﬂammation and inhibition
of both immunocyte and epithelial cell apoptosis. Additionally, key genes regulated downstream of gp130
via MAPK activation such as the stomach-speciﬁc tumor suppressor gene tff1 are suppressed, contributing to
the oncogenic outcome. The main cytokine driver of gp130 signalling in the stomach is IL-11, with IL-6
having little activity in the antral stomach in which most pathology initiates. IL-11 is up-regulated in both
mouse and human gastric cancer and in pre-neoplastic mucosa. A characteristic gene signature speciﬁcally
associated with IL-11 drive has been observed, although the prognostic value of the signature has not yet
been assessed. Infection of human or mouse stomach with Helicobacter pylori, especially that expressing the
CagA cytotoxin, produces constitutive MAPK activation, but also activated STAT3 and increases IL-11
expression. The possibility of designing and utilising small molecule inhibitors of either IL-11 or STAT3
activation may be worthwhile in developing new cancer therapeutics.
© 2009 Elsevier B.V. All rights reserved.1. gp130 cytokines and homeostatic signalling in the
gastric mucosa
The interleukin-6 (IL-6) family of cytokines are ligands for the
signalling receptor subunit glycoprotein 130 (gp130) [1,2]. IL-6 family
cytokine members include IL-6, interleukin-11 (IL-11), ciliary neuro-
trophic factor (CNTF), cardiotrophin-1 (CT-1), cardiotrophin like
cytokine (CLC), leukaemia inhibitory factor (LIF), oncostatin M (OSM),
neuropoitin (NPN) and interleukin-27 (IL-27) [1,2]. Recently IL-31 has
been assigned to the IL-6 family of cytokines, as it also signals through a
gp130-like receptor [3]. IL-6 and IL-11 are the dominant IL-6 family
cytokines in terms of expression in the gastric mucosa, and are the only
cytokines of the family that exclusively utilise gp130 homodimers.
To transduce their signal, IL-6 and IL-11 must bind their speciﬁc α
receptor subunits (IL-6Rα and IL-11Rα), this complex then associates
with gp130 homodimers (picomolar afﬁnity), creating a hexameric
complex of 2 molecules of ligand, 2 molecules of α receptor (gp80)
and 2 molecules of gp130 [4,5]. Naturally occurring, soluble forms of
IL-6Rα (sIL-6Rα) and gp130 (sgp130) also exist [6,7]. The sIL-
6Rα arises from speciﬁc cleavage of membrane bound IL-6Rα by
endogenous enzymes, or through alternative splicing events [8–10].at tel.: +61 3 8341 6446. L.M.
rens Hospital, Flemington Rd,
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ll rights reserved.sIL-6Rα lacks the transmembrane domain of IL-6Rα and binds IL-6
with a nanomolar afﬁnity [2]. The sIL-6Rα allows transductionof gp130
signallingwithout theneed formembraneboundα receptors, rendering
cells that lack the membrane bound form of IL-6Rα capable of IL-6
signalling, or trans-signalling. However, sIL-6Rα also confers antago-
nistic properties on gp130 signalling in the presence of sgp130. This
antagonistic property is thought to arise from the IL-6-sIL-6Rα complex
binding to sgp130, which cannot transduce signalling, due to the lack of
a transmembrane domain [11,12]. This renders the sIL-6Rα both an
agonist and antagonist of gp130 (reviewed in [13]). Although Karow et
al constructed a sIL-11Rα, which lacked the transmembrane domain
andwas capable of transducing IL-11mediated gp130 signalling [14], to
date, a naturally occurring soluble form of the IL-11Rα has not been
identiﬁed.
Following gp130 receptor activation, three alternate signalling
pathways can be activated (Fig. 1). In the ﬁrst, signalling is mediated
by the janus kinase (JAK)/signal transducer and activator of
transcription (STAT) pathway [1]. In mouse, protein kinases JAK1,
JAK2 and TYK2 phosphorylate tyrosine (Y) residues Y765, Y812, Y904
and Y914 located on the cytoplasmic tail of gp130. In human, the
residues are located at Y767, Y814, Y905 and Y915 [15,16]. This
phosphorylation potently activates the transcription factor STAT3 and
to a lesser extent STAT1 [17]. In the second pathway, the src-
homology domain protein tyrosine phosphatase-2 (SHP-2)/extracel-
lular signal-regulated kinase (ERK)/mitogen activated protein kinase
(MAPK) cascade can be activated by phosphorylation of a single
tyrosine on gp130, tyrosine (Y)757 in mice and Y759 in humans [15].
1624 M. Howlett et al. / Biochimica et Biophysica Acta 1793 (2009) 1623–1633Activation of SHP-2 and its subsequent binding to Y757/759 on gp130
is the critical initiating event for the SHP-2/ERK/MAPK pathway.
Finally, activation of the Schmidt-Ruppin A-2 viral oncogene (Src)
kinase family member, phosphoinositide 3-kinase (PI3) kinase/
protein kinase B (AKT) can also occur downstream of gp130 [18],
although these signalling events are less well understood and most
likely involve phosphorylation of JAK2 [19,20] (Fig. 1).
2. Deregulation of gp130 signalling in gastric cancer
Under homeostatic conditions, these three gp130 signalling
pathways are tightly controlled by multiple negative feedback
mechanisms, which balance effector outputs from each pathway
[21,22]. Suppressor of cytokine signalling (SOCS) proteins in part
mediate this negative feedback. SOCS1 binds to phosphorylated JAKs,
while SOCS3 binds directly to the phosphorylated Y757/759 residue
on gp130, thereby blocking JAK activation as well as the downstream
STAT signalling cascade [21,22] (Fig. 1). SHP2 is also recruited to the
Y757/759 residue on gp130 and inhibits STAT activation in a similar
way to SOCS3 [22,23].
The SHP2/ERK/MAPK pathway can regulate many processes
important in carcinogenesis including cell proliferation, morphogen-
esis and cell survival [24,25]. Constitutive phosphorylation of ERK
(pERK) 1/2 has been demonstrated in numerous cancers including
leukaemia [26], breast [27], ovarian [28,29], prostate [30] and
oesophageal [31]. Inhibition of pERK in ovarian cancer-derived cells
in vitro also inhibits growth [29], suggesting that constitutive pERKFig. 1.Homeostatic gp130 signalling following ligand-induced receptor activation can trigger
conditions, these pathways are under the tight control of negative feedback elements, ma
activated JAKs while SOCS3 binds to Y757 on gp130 and deregulates STAT3 signalling. Phoexpression is pathogenic. Deregulation of SHP-2/MAPK/ERK signal-
ling may have some speciﬁc relevance in the pathogenesis of gastric
cancer. Phosphorylated cytotoxin antigen A (CagA) binds intracellular
SHP-2 during Helicobacter pylori (H. pylori) infection, causing
constitutive up-regulation of pERK1/2 in vitro [32] and we have
recently demonstrated that pERK1/2 is also up-regulated in CagA-
positive H. pylori infected human gastric biopsies [33]. Activation of
ERK is required for the morphological transformation that occurs in
epithelial cells as a result of CagA-positive, H. pylori infection in vitro
known as the “hummingbird” phenotype [32]. The hummingbird
phenotype is a highly motile cell phenotype [34], so the requirement
for pERK suggests that it may also be involved in cell migration during
carcinogenesis.
In contrast to cell lines, examination of human gastric cancer
specimens surprisingly showed a signiﬁcant decrease in pERK1/2
expression compared to non-cancerous, adjacent tissues [35]. This
suggests that gastric cancer cells acquire the ability to attenuate ERK
signalling, perhaps through expression of inhibitory molecules, or
through the interruption of regulatory feedback mechanisms. There-
fore, the regulation of ERK signalling in gastric cancer progression is
complex and as yet, not well understood. What does remain clear
though, is that deregulation of ERK signalling, whether it be increased
or decreased seems important both in H. pylori infection in
progression toward gastric cancer, as well as maintenance of the
solid tumor.
Constitutive up-regulation of phosphorylated STAT3 (pSTAT3), an
alternate transcription factor emanating from the gp130 signallingthree signalling cascades; the JAK/STAT, SHP2/ERK or AKT cascades. Under homeostatic
rked as blunt end lines. Suppressor of cytokine signalling (SOCS)-1 binds directly to
sphorylation of SHP-2 can also directly attenuate STAT3 signalling. Based on [2,15,18].
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as well as primary tumors in the breast, head and neck, prostate, skin,
ovaries, lung, brain, pancreas and kidney (reviewed in [36]). In many
of the cancer-derived cell lines, constitutive pSTAT3 is absolutely
required for growth, as demonstrated by the induction of apoptosis
and/or growth arrest following the blockade of STAT3 activation by
small interfering ribonucleic acid (si)RNA, dominant negative con-
structs, or speciﬁc inhibitory compounds [37–41]. Reduced STAT3
activation is accompanied by down-regulation of a number of genes
involved in cell cycle progression, anti-apoptosis, angiogenesis, tumor
cell invasion and inﬂammation, demonstrating that aberrant expres-
sion of STAT3 is crucial for many aspects of tumorigenesis.
Constitutive pSTAT3 expression is also implicated in gastrointestinal
carcinogenesis. Several reports demonstrate increased expression of
pSTAT3 in colonic and colorectal cancers [41,42], where high expression
is a marker of poor prognosis [43]. Constitutive pSTAT3 has been linked
with colorectal cancer cell invasion in vitro by up regulation of various
invasive genes such as vascular endothelial growth factor (VEGF) and
MMP's [39,41]. In the stomach, pSTAT3expression is greatly increased in
H.pylori infection aswell as in gastric cancer [33,44] and ingastric cancer
cell lines [33,59–61]. Moreover, STAT3 activation correlates with
decreased survival of gastric cancer patients [45,46], strongly demon-
strating a potential pathogenic role.
To date, nomutations have been identiﬁed in the human STAT3gene
that explains its constitutive activation in somany cancers. This suggests
that deregulation of the negative feedback SOCS proteins, or over-
stimulation of gp130 by IL-6 family cytokine production may be
responsible for its hyperactivation. Evidence to support this comes from
transgenic models in which chronic activation of gp130 leads to hepatic
adenoma formation [107], and more recently somatic mutations in
gp130, evident in 60% of inﬂammatory hepatocellular adenomas have
been described, which render the receptor capable of dimerisationwith
either mutated or wild type receptor molecules, and in the absence of
ligand, result in constitutive activation of STAT3 [47]. Thismutationdoes
not produce ERK 1/2 activation and although SOCS3 is induced, its
ability to negatively regulate STAT3 signalling appears to be over-
whelmed [47]. These observations, although not yet replicated in the
stomach, provide further evidence for the importance of deregulated
gp130 signalling in gastrointestinal carcinogenesis.3. A mouse model of dysregulated gp130 signalling results in
gastric tumorigenesis that recapitulates most developmental
stages of human intestinal-type gastric cancer
gp130 homozygous knockout mice die at embryonic day 12.5 [48]
and similarly, homozygous STAT3 knockout mice die even earlier at
embryonic day 6.5 to 7.5 [49], emphasising the importance of this
receptor signalling pathway in fetal development. Conversely, a
mouse with a speciﬁc global “knock-in” mutation on gp130 has been
developed to investigate the role of gp130 ligands and signalling
pathways in haematopoiesis and inﬂammation. Signiﬁcantly this
mouse is viable, despite minor blood cell and inﬂammatory joint
phenotypes, however the dominant pathological outcome is the rapid
development of gastric tumorigenesis [50].
The knock-in mutation is located at Y757 on gp130, whereby the
tyrosine is substituted with a phenylalanine (F) on both alleles, hence
the name gp130757FF mouse. The knock-in mutation prevents SHP-2
binding to gp130 in response to receptor activation by endogenous IL-6
family cytokines, thereby preventing SHP-2 phosphorylation and
ablating signalling through the SHP2/ERK/MAPK transduction cascade
[50] (Fig. 2). As Y757 is also the docking site for SOCS3, the negative
feedback loop for STAT3 signalling is also ablated in these mice. The
effect is unbalancedgp130signallingoutput,withblockadeof theSHP2/
ERK/MAPKpathwayand constitutive up-regulation of the JAK/STAT1/3
pathway via gp130 [50] (Fig. 2).Homozygous mutant gp130757FF mice are born with the expected
Mendelian inheritance ratio and develop and behave like WT mice.
However, young adult mice exhibit splenomegaly and develop
gastric tumors in the antral stomach [50]. Gastric tumor develop-
ment in gp130757FF mice follows many of the steps deﬁned by
Correa's model of intestinal-type gastric cancer progression in
humans, including chronic gastric inﬂammation (gastritis), glandu-
lar atrophy, intestinal-type mucous metaplasia, dysplasia and
development of submucosal invasion at a later age, making them
an excellent model to study gastric cancer progression [51].
However, as with the majority of mouse gastric cancer models,
limitation of the model arises in the lack of primary tumor spread to
other organs, with the result that mice do not die from the effects of
disseminated gastric metastases, but most likely from global
cytokine stress [51].
gp130757FF tumors are 100% penetrant and develop in a site
speciﬁc, gender-independent, time-dependent manner [51]. At 4–
6 weeks of age, gp130757FF tumors are evident as discrete masses in
the antral stomach, with associated inﬂammatory cell inﬁltration and
occasional small gastric ulcerative lesions [51]. Tumors rapidly spread
along the lesser curvature of the stomach to eventually encapsulate
the entire antral and fundic regions by approximately 20 weeks of age,
when limited submucosal invasion also develops [51]. Tumor-
associated gastritis consisting of mucosal and trans-mural polymor-
phonuclear as well as mononuclear cell inﬁltrate persists throughout
the entire process [52].
gp130757FF tumor development is very robust, as tumors develop
identically on both C57Bl6/129Sv/J and C57Bl6 backgrounds and
growth occurs at the same rate in speciﬁc pathogen free as well as
conventional animal facilities. Unlike many other mouse models,
gastric tumors develop and progress in a hypogastrinaemic environ-
ment and without the requirement for constitutive activation of the
epidermal growth factor receptor (EGF-R), although EGF-R, heparin-
binding epidermal growth factor (HB-EGF) and transforming growth
factor α (TGF-α) expression are increased during the most rapid
phase of tumorigenesis, between the ages of 12 and 16 weeks [51].
Some other genes typically associated with gastric cancer develop-
ment are also changed in gp130757FF tumors, including the tumor
suppressor Trefoil factor 1 (TFF1), which is strongly down-regulated,
regenerating islet-derived protein (Reg) family members RegI,
RegIIIβ, RegIIIγ and cancer associated metalloproteinases (MMPs),
which are all substantially increased [51,53].
Constitutive activation of STAT3 causes tumorigenesis in gp130757FF
mice, asdemonstratedby theanalysis of compoundgp130757FFSTAT3+/−
mutants [53]. gp130757FFSTAT3+/−mice have signiﬁcantly smaller
tumors, with reduced expression of MMPs and Regs, demonstrating
that these genes are both STAT3-dependent and pro-tumorigenic
[53]. Gastric inﬂammation as well as expression of associated pro-
inﬂammatory cytokines and chemokines is also reduced in
gp130757FFSTAT3+/− mice and chronic treatment of gp130757FF
mice with antibiotics reduces tumor mass by reducing the number of
activated macrophages in the gastric mucosa [53]. Moreover, neither
gp130757FF recombination activating gene 1(Rag1)−/− mice,
which lack T, B and natural killer T cells (NKT) cells, nor gp130757FF
perforin−/−mice, which have diminished cytotoxic T cell function
have altered tumor development [52]. Informative mutations on the
gp130757FF background are summarised in Table 2. These data
suggest that of the inﬂammatory cells present during gp130757FF
gastritis, macrophages likely play an aggressive tumor-promoting
role. This view is in accordance with a growing body of evidence
accumulated fromdifferent cancers, which supports a role for tumor-
associated macrophages promoting tumor development by produc-
ing matrix MMP and growth factors, as well as suppressing host
adaptive immunity and promoting angiogenesis [116]. It is also likely
that stromal cells of the tumor microenvironment like neutrophils
[117], mast cells [118] and ﬁbroblasts [119] may also modulate
Fig. 2. Deregulated gp130 signalling in gp130757F/F mice where phenylalanine (F) has been “knocked in” to substitute the tyrosine residue at position 757 on gp130. The result is
unbalanced gp130 signalling output, with blockade of the SHP2/MAPK/ERK pathway and constitutive up-regulation of the JAK/STAT1/3 pathway, causing development of gastric
antral tumors.
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regulation.
4. IL-6 is dispensable but IL-11 signalling is absolutely required to
drive chronic gp130/STAT3 activation
The gp130 ligands, IL-6 and IL-11 are strongly up-regulated in
gp130757FF tumors [52]. To assess the contribution of IL-6 in tumorigen-
esis, compound gp130757FF IL-6−/−mutant mice were characterised. As
IL-6 is a major gp130 ligand as well as a pro-inﬂammatory cytokine with
established roles in inﬂammatory cell recruitment, it was hypothesised
that both STAT3 activation and gastritis would be diminished in these
mice, predicted to result in decreased tumorigenesis. Although mononu-Table 1
Fold changes in IL-11-associated gene signature in mouse and human gastric pathology com
Mouse
Fold change up (+), down (−) vs. normal gastric antrum
Gene WT antrum+IL-11 (5 µg) gp130757FF antrum
Clusterin +2 +14
GREM1 +2 +3
Reg IIIβ/αa +250 +1500
Reg IIIγ +110 +220
GAS-1 −4 −10
a The closest structural human equivalent to mouse Reg IIIβ is RegIIIα. No human RegIIIβclear cell inﬁltration and Ig production in gp130757FF IL-6−/− mice are
diminished, the absence of IL-6 has no effect on STAT3 activation or
tumorigenesis [52]. In fact, IL-6 is dispensable for tumorigenesis in
gp130757FFmice, as gp130757FF IL-6−/−micedevelop tumors of the same
size and with the same growth characteristics as their gp130757FF
littermates [52,54].
Interestingly, IL-11 expression was signiﬁcantly increased in
gp130757FF IL-6−/− mice, concomitant with undiminished hyper-
activation of STAT3 compared to gp130757FF mice [52], suggesting that
IL-11 drives STAT3 activation in the gastric mucosa of these mice.
Moreover, gp130757FF IL-6−/− mice have increased tumor invasion
into the submucosa at all ages examined, with evidence of tumor cells
encapsulated by blood vessels in the submucosa [52]. This suggestspared to the normal antral stomach.
Human
Fold change up (+) or down (−) vs. normal gastric antrum
H.pyloriCagA+
biopsy








Genetic crosses made with gp130757F/F mouse and effects on gastric tumor growth in
comparison with age-matched gp130757F/F littermates.
Genetic cross Outcome compared to gp130757F/F Reference
gp130757F/F×IL-11Rα−/− No tumor growth [55,54]
gp130757F/F×IL-6−/− Same tumor growth [52,54]
gp130757F/F×STAT3+/− Much less tumor growth [53,54]
gp130757F/F×RAG1−/− Same tumor growth [52]
gp130757F/F×STAT1−/− Less tumor growth [54]
gp130757F/F×STAT1+/− Less tumor growth [54]
gp130757F/F×perforin−/− Same tumor growth [52]
gp130757F/F×A33−/− Same tumor growth Unpublished
gp130757F/F×MMP13−/− Same tumor growth Unpublished
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IL-11 may be a key regulator of gastric tumor progression, with as yet
unrecognised roles in tumor invasion and outcome.
In order to assess the role of IL-11 directly in antral hyperplasia and
tumorigenesis, gp130757F/F/IL-11Rα−/− mice were generated
[54,55], and tumor progression was assessed. Loss of IL-11Rα
prevented gastric inﬂammation, STAT3 activation and tumor initia-
tion, demonstrating the absolute requirement for IL-11 signalling for
tumor induction in this model. In addition, a single high dose of
recombinant hIL-11 in wildtype mice induced exactly the same
pattern; hyperactivated STAT3, with no induction of pERK. IL-6 could
not induce any detectable signalling in the antrum, and commensu-
rate with the pathology of gp130757F/F IL-6−/− mice [52,55].
The importance of IL-11 signalling in gastric pathology is further
supported by the gastric phenotypes of hydrogen/potassium adeno-
sine triphosphatase (H+K+ ATPase) subunit β−/− mice, which
develop gastrin-dependent, gross fundic hyperplasia by 12 weeks of
age [56] and transgenic K19-C2mEmice, engineered to simultaneous-
ly overexpress cyclooxygenase-2 and microsomal prostaglandin E
synthase-1, which develop hyperplastic fundic tumors by 48 weeks of
age [57], and when crossed with K19-Wnt-1 transgenic mice (K19-
Wnt-1/C2mE) produce large, dysplastic fundic tumors by 30 weeks of
age [58]. Gastric IL-11 expression is increased 10–25 fold compared to
wildtype strain controls in each of these models, and is associated
with hyperplasia and inﬂammation in each case [55].
In humans, elevated IL-11/STAT3 expression accompanies the
development of gastric cancer. Gastritic antral stomach associated
with H. pylori expression shows increased STAT3 activation [33], and
both metaplastic stomach and adenocarcinomas synthesise IL-11 at
levels 5–15 fold that of normal antrum [55]. It is likely that the
increase in IL-11/STAT3 accompanying tumorigenesis promotes
tumor proliferation and longevity in evading apoptosis [33,59–61].
The cellular source of tumor-associated IL-11 has not been estab-
lished, and it is not clear whether epithelial growth is regulated by
autocrine or paracrine mechanisms emanating from the tumor
epithelium or by tumor-associated stromal cells. The future use of
sensitive and speciﬁc monoclonal antisera and staining protocols for
immunodetection of IL-11 protein [11], coupled with co-staining of
speciﬁc markers of the stromal and epithelial compartments, as well
as in vitro studies using gastric cell lines known to express IL-11 and/
or the IL-11α receptor [33] will help resolve these issues.
Despite the lack of a substantive role for IL-6 in driving gastric
tumor progression in the gp130757F/F mouse, this cytokine is
expressed in human stomach, and elevated expression accompanies
progression of precancerous lesions [33] as well as gastric adenocar-
cinoma development [33,108]. Moreover, serum IL-6 is positively
correlated with stage, lymphatic invasion and metastasis [109,110]
and negatively with gastric cancer survival [110], although known IL-6 polymorphisms appear not to be associated with the risk of
adenocarcinoma development [111]. IL-6 is a potent pleiotrophic
cytokine produced by most immunocyte classes, particularly myeloid
cells in the tumor microenvironment, and which can activate STAT3
via gp130 in both epithelial and immune cells [112]. IL-6 plays a
central role in cytokine induction and leucocyte recruitment [113],
and regulates the neutrophil to monocyte transition accompanying
the inﬂammatory response [114,115]. Thus, it is possible that IL-6may
play an important contributory role in H. pylori-induced chronic
gastritis and other pre-neoplastic lesions in human gastric cancer
development.
5. Constitutive IL-11/STAT3 activation induces a characteristic
gene signature that may promote gastric cancer progression
To identify genes regulated by IL-11 in the gastric mucosa, cDNA
microarray on antral tissue from WT mice treated with a single 5 μg
dose of recombinant hIL-11 (i.p.) and compared to sham controls was
performed [55]. The most differentially expressed genes were chosen
for further evaluation, and several of these including SOCS-3 and
gp130 are known targets of IL-11. Quantitative polymerase chain
reaction (QPCR) was performed to validate a selection of genes with
established functions in proliferation and apoptosis. Growth factors
RegIIIβ and RegIIIγ, Clusterin and Gremlin-1 were all increased while
apoptotic GAS-1 was decreased. A very similar pattern was found in
mouse gp130757F/F antral tumors, and in mouse H+K+ ATPase β−/−
stomach, emphasising the utility of these genes in marking oncogenic
phenotypes in genetic models. The 5 gene signature was also
signiﬁcantly and co-ordinately changed in human H. pylori-associated
gastritis, metaplastic antrum and adenocarcinoma of the stomach by
QPCR, with the Reg genes being up-regulated in precancerous lesions,
Clusterin and Gremlin strongly induced in all pathology, and GAS-1
being induced in metaplasia and cancer [55] (Table 1). Together the
data suggest that relative changes in this gene signature may be
diagnostic for neoplastic progression associated with IL-11 drive in
the gastric mucosa. In addition, IL-11, SOCS3, cyclin D1 and MMP13
are differentially expressed between gp130757F/F and gp130757F/F/IL-
11Rα−/− antral stomach [54] conﬁrming the key role IL-11 plays in
promoting proliferation and the invasive epithelial phenotype.
6. H. pylori infection and CagA cytotoxin promotes IL-11/STAT3
signalling in human gastric cancer cell lines
It is clear from clinical studies [59] and animal models [54,55] that
imbalanced cytokine signalling, involving the inappropriate activation
of STAT3 pathway by IL-11, disrupts gastric homeostasis predisposing
to stomach pathology including tumorigenesis. By contrast, rather less
is known about IL-11/STAT3 signalling in the context of H. pylori
infection, a key initiating factor in gastric cancer development.
H. pylori is an enteric bacterium that exerts a profound inﬂuence
upon the development of intestinal-type gastric adenocarcinoma,
resulting in its designation as a type I carcinogen by the World Health
Organisation [62]. Whilst the oncogenic potential of H. pylori is
undoubted, the molecular mechanisms by which it disrupts gastric
homeostasis in the progression of cancer are not yet fully apparent. In
this capacity, much attention has been devoted to CagA, a high
molecular weight (120–145 kDa) immunodominant protein of H.
pylori that is encoded by the cagA virulence gene. The cagA gene is
located within the cag pathogenicity island (cagPAI), a 40 kilobase
(kb) genomic DNA region containing 27–31 virulence genes, some of
which encode components of a bacterial type IV secretion system
(T4SS) which is required for the translocation of CagA into gastric
epithelial cells. A substantial body of evidence has shown that CagA-
positive H. pylori strains are more virulent than CagA-negative strains,
promote higher grade gastric inﬂammation, and are associated with
an increased risk of gastric adenocarcinoma [63]. Functional evidence
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where CagA overexpression under an H+/K+ ATPase β-subunit
promoter leads to uniform overgrowth of the gastric epithelium and
late onset focal tumorigenesis of partial penetrance [64], the latter
implicating the contribution of secondary somatic mutations. CagA
has also been shown to mediate oncogenic transformation of normal
gastric epithelial cells by rat sarcoma virus oncogene (Ras)-indepen-
dent activation of ERK1/2 kinase signalling [65]. Therefore, CagA is a
bacterial oncoprotein that is functionally active in mammalian cells
and may promote tumorigenesis in susceptible individuals.
Current literature indicates that CagA-positive H. pylori strains
directly inject CagA into host cells via the type 4 secretion system
(T4SS) which is considered to function as a ‘molecular syringe’ [66].
This mode of delivery of CagA into host epithelial cells has provided
unique opportunities to study the intracellular signalling events that
underlie this key mechanism of H. pylori pathogenicity. Some of these
signalling events impact on IL-6 family cytokine signalling down-
stream of the gp130 co-receptor. Upon entry to host cells, CagA
tethers to the inner surface of the plasma membrane [67] and
undergoes tyrosine phosphorylation at speciﬁc C-terminal Glu-Pro-
Ile-Tyr-Ala (EPIYA) repeat motifs [32], initially by src-family kinases,
with ongoing phosphorylation maintained by the cytoplasmic protein
kinase, c-Abl [68]. CagA has been shown to interact with several
intracellular signalling molecules in both phosphorylation-dependent
and phosphorylation-independent contexts. Phosphorylation-depen-
dent binding to CagA most likely occurs by virtue of exposed
phosphotyrosine residues in the EPIYA repeats which act as dockingFig. 3. Schematic representation of hyperactivated gp130sites for cognate SH2-domain containing proteins including the C-
terminal Src-kinase (Csk) [69], the adaptor molecule avian sarcoma
virus CT10 (Crk) [70] and most signiﬁcantly the oncoprotein, SHP-2
[32]. CagA has also been shown to interact with the adapter molecule
growth factor receptor bound (Grb2) [71], and the hepatocyte growth
factor (c-Met) receptor [72] in a phosphorylation-independent
manner, although it should be noted that the Grb2, interaction is
quite weak, and arguably, is less physiologically relevant than the
stronger phosphorylation-dependent reaction with SHP-2 [34].
The best characterised of the intracellular targets of CagA is SHP-2
which speciﬁcally binds tyrosine phosphorylated CagA and provokes
inappropriate signalling via the canonical SHP-2-ERK/MAPK cascade
leading to characteristic cell elongation and increasedmotility termed
the hummingbird phenotype[32,65,73] (Fig. 3). RNA interference
mediated knockdown of SHP-2 expression blocks both ERK activation
and the establishment of the hummingbird phenotype induced by
CagA [34]. Thus SHP-2 is an intracellular mediator of CagA function in
gastric epithelial cells. This is intriguing, since SHP-2 is a critical
transducer of IL6-family cytokine signalling downstream of the gp130
co-receptor, and as illustrated by studies in gp130757FF mice
[50,51,74], perturbation of SHP-2 activity can elicit severe patholog-
ical outcomes in the stomach. More recent work demonstrates that
binding of SHP-2 by CagA also requires multimerization of CagA.
Multimerization, suggested to occur by homodimerisation of two
CagA monomers, occurs independently of EPIYA tyrosine phosphor-
ylation and instead requires a Cag multimerization (CM) sequence
located in the C-terminal EPIYA repeat region [75]. Therefore, CagAsignalling following CagA-positive, H. pylori infection.
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H. pylori to manipulate host cell physiology by the inappropriate
activation of SHP-2.
Disruption of SHP-2 binding to the gp130 co-receptor in gp130757FF
mice imbalances both SHP-2-ras-ERK and STAT1/3 pathways that
initiate from gp130, resulting in an exaggerated and constitutive
STAT3 response that is fully sufﬁcient for gastric tumorigenesis
[50,51,53,76]. We have also shown increased STAT3 activation in
CagA-positive compared with CagA-negative H. pylori infections in
precancerous lesions of humans [33], thus arguing for exaggerated
STAT3 signalling driven by CagA. Experiments in other organ systems
have established that constitutive STAT3 activation is oncogenic [77],
and together these studies strongly implicate STAT3 as a mediator of
CagA-induced gastric cancer progression. Besides activating the ERK/
MAPK pathway, SHP-2 has also been reported to negatively regulate
STAT3 activation by acting as a tyrosine phosphatase [74]. In this
context, a possible explanation for the dysregulation of STAT3 by CagAFig. 4. Schematic representation of the multiple IL-11 and STAT3 inhibitors anis that sequestration of SHP-2 by CagA, restricts access to its cognate
cellular substrates thus releasing STAT3 from negative feedback
inhibition (Fig. 3). Signalling via IL-11 is another mechanism that
could explain elevated STAT3 phosphorylation in response to CagA
(Fig. 3). In support of this hypothesis, Murata-Kamiya et al. identiﬁed
IL-11 as one of the several target genes up-regulated on expression
microarrays after forced expression of CagA in MKN28 gastric
epithelial cells, although the activation status of STAT3 was not
determined [78]. More direct evidence of an autocrine mechanism of
IL-11/STAT3 activation by CagA comes from work done in our
laboratory showing that tyrosine-phosphorylated WT CagA, but not
a phosphorylation resistant (PR)-CagA mutant, provokes increased
STAT3 phosphorylation and IL-11 expression in both MKN28 and AGS
cells (T.R. Menheniott, unpublishedwork). Therefore, CagA stimulates
IL-11/STAT3 signalling in gastric epithelial cells in a phosphorylation-
dependent context. In contrast to our observations, a recent study
reports IL-6- and IL-11-independent activation of STAT3 signalling byd their point of action on the gp130 induced STAT3 transduction cascade.
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[79], although we note that these experiments were carried out in the
non-gastric, HeLa cell-derived HEp-2 cell line, thus sounding a note of
warning over extrapolation of these ﬁndings to the stomach.
7. Novel inhibitors of IL-11 or STAT3 as potential gastric cancer
therapeutics
Recent work on IL-6 family cytokine signalling in gastric cancer
suggests a major role for IL-11/STAT3 in regulating tumor prolifer-
ation, angiogenesis and apoptosis. IL-6 activation of gp130 produces
signalling outcomes predominantly via MAP-dependent mechanisms
which likely targets recruitment of inﬂammatory cells to the tumor
microenvironment [33]. It follows that inhibition of IL-11 binding,
STAT3 activation or transcription of target genes, may form the basis
of new and selective therapeutics. Indeed, STAT3 is widely perceived
to be a likely target in this regard since it has been implicated in the
progression and metastasis of many, mainly epithelial cancers such as
those of the lung [80], prostate [81], breast [82], colon [83], and bile
duct [84].
7.1. IL-11 receptor antagonists
Several IL-11 receptor antagonists have been described. W147A,
named for a binding site tryptophan analog of IL-11 [85] is a high
afﬁnity antagonist (nM) which disrupts multimeric gp130/IL-11Rα
complex formation in Ba/F3 and primary human endometrial cells
(Fig. 4) [86]. W147A is large (~20kDa) with a tertiary structure very
similar to IL-11, and although readily synthesized in E. coli, may be
more difﬁcult to produce in bulk for use as a cancer therapeutic than
small molecule inhibitors or truncated versions with antagonist
activity.
Recently, another IL-11 antagonist known as PEGylated IL-11A has
been produced [87]. IL-11 is integral to the receptive uterine response
to blastocyst implantation, and PEGylated IL-11A has been shown to
inhibit IL-11 action and prevent pregnancy in amousemodel [88]. The
antagonist binds IL-11Rα, preventing docking to gp130 and disrupt-
ing signal transduction [87] at least in part by preventing STAT3
phosphorylation, as demonstrated in human endometrial HES cells
(Fig. 4) [88]. It is likely that this inhibitor will also be useful in
inhibiting gastric tumor growth in a similar fashion when it becomes
commercially available. In addition, future generation of highly
speciﬁc neutralizing monoclonal antibodies to the IL-11α receptor,
such as the clinically useful anti-IL-6R antibody may also be applied
therapeutically [120].
7.2. STAT3 inhibitors
Because of its ubiquity in promoting the cancer phenotype when
constitutively activated [77,89], and because it is a common mediator
of transcriptional outcomes in tumors driven by cytokines, growth
factors and immunological regulators, STAT3 is regarded as an
excellent drug target.
STAT3 inhibitors can be selected or designed to act selectively at
multiple points in the gp130 signal transduction cascade (Fig. 4). Thus
JAK2 inhibitors, and inhibitors of STAT3 dimerization, recruitment or
DNA binding have been described, and show variable degrees of
utility when tested in vitro or less commonly in vivo. The challenge is
to produce speciﬁc, potent, low molecular weight, and low cost
inhibitors which might be given intravenously or orally and with few
deleterious side effects.
Apart from the endogenous protein regulators of STAT3; SOCS3
[90], protein inhibitor of activated STAT3 (PIAS3) [91], SHP phospha-
tases [92], GRIM19 [93,94] and Grb2 [95], there are numerous natural
and synthetic small molecule products which inhibit STAT3, many of
which have been reviewed recently [96]. Prominent among these areinhibitors of STAT3 or JAK2 phosphorylation or both, including
curcumin an active ingredient of tumeric, the cyclopentenone family,
resveratol a phytoalexin, and the family of cucurbitacins, [97,98];
ﬂavopiridol which inhibits STAT3 binding to DNA [99]; deoxytetran-
gomycin, an antibiotic that prevents STAT3 dimerisation [100]; dual
inhibitors of STAT3 phosphorylation and DNA binding such as the
bacterial quorum-sensing bacterial molecule N-acylhomoserine lac-
tone [101] and indirubin the active ingredient of certain Chinese
herbal medicines [102]; cisplatin and derivatives which de-phos-
phorylate JAK2 and STAT3 [103]; STA-21 [100] and small phospho-
peptides which inhibit DNA-STAT3 binding and dimerization; and
Guggulsterone, a farnesoid X receptor antagonist blocks STAT3
activation via c-Src and JAK2 inhibition and by stimulating SHP1
phosphatase activity [104]. STAT3 antisense oligonucleotides have
also been shown to be effective in vivo in restricting gastric tumor
growth [54].
Recently we have tested several caffeic acid derivatives related to
the tyrphostin AG 490 which is a low potency JAK2 inhibitor. WP1066,
which has previously been demonstrated to inhibit STAT3 activation in
vitro and slowed the growth of malignant glioma cells in vivo by
promoting apoptosis [105]was used.We have shown similar potency of
WP1066 in inhibiting JAK2 and STAT3 phosphorylation in gastric cancer
cell lines, and it is efﬁcacious in blocking gastric tumor progression in
the gp130757FF mouse [106] by similar means resulting in loss of
mitogenic drive and reduced tumor-associated inﬂammation.
These STAT3 inhibitors enumerated above have low molecular
weight, are effective at micromolar concentrations in vitro, and most
have multiple inhibitory actions on different signalling pathways to
potentially inhibit tumor growth, attendant inﬂammation, as well as
promoting tumor cell apoptosis. To date few have been tested in vivo
and thus issues around the most effective route of administration and
unwanted side effects are not well understood. Nonetheless, the
likelihood of clinical trials of STAT3 inhibitors alone, or in combination
with other therapeutics which target different signalling pathways
are likely in the near future.
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